Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.65 |
| ▸ | QDPR | P09417 | 3/20 | 0.54 |
| ▸ | KHK | P50053 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9532611 | 0.98 | HTR2C (0.67) | HTR2CSIGMAR1QDPRKHKHTR7 | |
| SCHEMBL3386020 | 0.83 | SIGMAR1 (0.59) | HTR2CSIGMAR1QDPRHTR7HTR2A | |
| SCHEMBL3686869 | 0.82 | HTR2C (0.44) | HTR2CSIGMAR1KHKHTR7HTR2A | |
| Hydrochloric Acid SCHEMBL28669700 | 0.82 | HTR2C (0.60) | HTR2CSIGMAR1QDPRHTR7HTR2A | |
| SCHEMBL4791120 | 0.81 | SIGMAR1 (0.79) | HTR2CSIGMAR1QDPRKHKHTR7 | |
| SCHEMBL6312184 | 0.80 | QDPR (0.55) | HTR2CSIGMAR1QDPRKHKHTR7 | |
| SCHEMBL532892 | 0.80 | HTR2C (0.66) | HTR2CSIGMAR1QDPRKHKHTR7 | |
| SCHEMBL6162512 | 0.79 | HTR2C (0.54) | HTR2CSIGMAR1QDPRKHKHTR6 | |
| Hydrochloric Acid SCHEMBL4793458 | 0.79 | HTR2C (0.79) | HTR2CSIGMAR1QDPRHTR7HTR2A | |
| SCHEMBL21228136 | 0.79 | HTR2C (0.66) | HTR2CSIGMAR1QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994196-B2 | Indazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| WO-2008015271-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THE USE AS A MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1226137-B8 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI AVENTIS (FR) | 2004-12-15 | — | — | EP | disclosed |
| EP-1226137-B1 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI SYNTHELABO (FR) | 2004-07-21 | — | — | EP | disclosed |
| US-6689797-B2 | TUMOUR NECROSIS FACTOR MODULATORS | SANOFI-SYNTHELABO (FR) | 2004-02-10 | — | — | US | disclosed |
| CN-1433412-A | Tetrahydropyridines, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2003-07-30 | — | — | CN | disclosed |
| US-20030083347-A1 | Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2003-05-01 | — | — | US | disclosed |
| US-6509351-B1 | A method of inhibiting TNF- alpha in a patient in need thereof which comprises administering to said patient an effective amount of a compound for inflamation | SANOFI-SYNTELABO (FR) | 2003-01-21 | — | — | US | disclosed |
| EP-1248785-A1 | NOVEL TETRAHYDROPYRIDINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sanofi-Aventis (FR) | 2002-10-16 | — | — | EP | disclosed |
| EP-1226137-A1 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI-SYNTHELABO (FR) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001049684-A1 | NOVEL TETRAHYDROPYRIDINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001029026-A1 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI-SYNTHELABO (FR) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | HTR2C 1793/4885SIGMAR1 3731/4885QDPR 658/4885 |
| US-20030083347-A1 | Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same | ADRB3, DRD3, CHRM3 | HTR2C 422/4885SIGMAR1 145/4885QDPR 6/4885 |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRIK5 | HTR2C 222/4885SIGMAR1 243/4885QDPR 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.